Response to 'Early Onset Drusen and RPE Dysfunction in a Patient with NLRP3-AID'.

"Response to ‘Early Onset Drusen and RPE Dysfunction in a Patient with NLRP3-AID’." Ocular Immunology and Inflammation, ahead-of-print(ahead-of-print), p. 1KEYWORDS: Inflammasomemacular degenerationgeographic atrophy Disclosure statementJ.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics, and he has been a consultant for AbbVie, Allergan, Boehringer-Ingelheim, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.A. and B.D.G. are cofounders of DiceRx. J.A. and B.D.G. are named as inventors on patent applications filed by their university.Additional informationFundingThe work was supported by the National Institutes of Health [R01EY032512]; National Institutes of Health [R01EY031039]; National Institutes of Health [R01EY029799]